• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
PVP-K30-----pharma excipients(CAS No.9003-39-8)
Tobramycin
Povidone iodine 20% powder
Povidone iodine 10% powder
SULBACTAM SODIUM STERILE
Food Additives Bulk Sucralose Neotame Advantame Powder

Lupin launches generic Vigamox Ophthalmic solution in the US

expressbpdJuly 06, 2017

Tag: lupin , Vigamox Ophthalmic solution , US

Lupin has announced the launch of its Moxifloxacin Hydrochloride Ophthalmic solution USP, 0.5 per cent (base) having received an approval from the United States Food and Drug Administration (FDA) earlier. The launched product is from Lupin’s Pithampur manufacturing facility.

Lupin’s Moxifloxacin Hydrochloride Ophthalmic solution USP, 0.5 per cent (base), is an AT1 rated generic equivalent of Novartis Pharms Corp.’s Vigamox Ophthalmic solution. It is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the organisms.

Previous:Alzheimer's and Parkinson's spurred by same enzyme

Next:Granules India gets board nod to raise foreign investment limit

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Lupin launches generic Vigamox Ophthalmic solution in the US | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

12 linnovativevacuum solidphase extraction apparatus

12 linnovativevacuum solidphase extraction apparatus
Cefadroxil Related Compound D (USP)

Cefadroxil Related Compound D (USP)
Marya GMP Standard Modular Clean Room Used Air Purifier Cargo Air Shower with Automatic Door

Marya GMP Standard Modular Clean Room Used Air Purifier Cargo Air Shower with Automatic Door
Industrial cryogenic treatment box

Industrial cryogenic treatment box

ChP, USP, EP Amphotericin B 1397-89-3

ChP, USP, EP Amphotericin B 1397-89-3
Estrone USP ≥97.0% API Hormone made in china

Estrone USP ≥97.0% API Hormone made in china
Aqueous Solution (EDTA)

Aqueous Solution (EDTA)
Enasidenib Api (for R&D use only)

Enasidenib Api (for R&D use only)
AS59-II Industrial dust collector

AS59-II Industrial dust collector
Sulfamethazine sodium salt BP/USP supplier API Pharmaceutical Sulfanilamide

Sulfamethazine sodium salt BP/USP supplier API Pharmaceutical Sulfanilamide

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service